Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global cancer therapeutics market size is expected to expand in the coming years. The demand for cancer therapeutics is powered by the increased government spending in R&D firms. The rising occurrence of cancer worldwide also increases the growth of the cancer therapeutics industry. Based on the application, breast cancer accounts for the largest market share in 2020 and, due to its high prevalence, the form of cancer is projected to remain dominant over the forecast period. Researchers at the ICR in London have confirmed that they have discovered a way to inhibit the escape of three negative breast cancer cells, and this new approach will interrupt the main mechanism in the progression of cancer. The team used a drug named BOS172722 from Boston Pharmaceuticals to rapidly differentiate cancer cells. Such developments are expected to drive the growth of the segment. In addition, breast cancer is also identified as the most prevalent cancer in the United States, which supports the segment's rise in the cancer therapeutics industry.
In March 2021, AbbVie (NYSE: ABBV), one of the key players in the industry, received a much-awaited approval for VENCLYXTO combination regime by the European Commission for patients with previously untreated chronic lymphocytic leukaemia. It is the third approval of VENCLYXTO, the first-ever B-cell lymphoma-2 (BCL-2) inhibitor. BCL-2 refers to a protein that prohibits apoptosis from occurring in cancer cells, a mechanism leading to the eventual death or self-destruction of cancer cells. VENCLYXTO is also approved for use in combination with rituximab for adult patients with CLL who have undergone at least one prior therapy and as in case of 17p deletion or TP53 mutation in adult patients who were not eligible for or failed a B- pathway inhibitor as a monotherapy in the treatment of CLL (chronic lymphocytic leukaemia).
Market Analysis by Top Selling Drugs, Application, and Regions:
Key Findings of the Report:
Key Offerings of the Report:
The major key players in the global cancer therapeutics market include companies like AbbVie Inc., Astellas Pharma Inc., Bristol Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc., among others. The comprehensive report covers their market share, capacity, and latest developments like mergers and acquisitions and capacity expansions.
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.